TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07126665: An Open-label Phase I/II Clinical Study of MHB088C for Injection Combined With MHB039A for Injection in Patients With Advanced Malignant Solid Tumors

Sponsor: Minghui Pharmaceutical (Hangzhou) Ltd · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 116 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$12,566,400

Rescue Site Savings

+$8,285,970

Unlock Full NCT07126665 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07126665 Rescue Dossier →